ISRCTN12117857进行中（未招募）1 期
Phase I trial: Parexel code: PXL 269850 [The full scientific title will be published within 30 months after the end of the trial]
MD Pharma0 个研究点目标入组 88 人开始时间: 2023年6月29日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial: Parexel Code: PXL277433The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN24909354Sanofi-Aventis Recherche & Développement88
进行中（未招募）
1 期
Phase I trial: PXL 272092ISRCTN45338135Hansa Biopharma (Sweden)8
进行中（未招募）
1 期
Phase I trial; HMR code: 24-003Healthy volunteersISRCTN16055614Sling Therapeutics, Inc.20
已完成
不适用
Phase II trial, multicenter, first line Paclitaxel-Avelumab Treatment for inoperable AngiosarcomaKCT0003334Dong-A University Hospital33
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12